Clinical Trials Directory

Trials / Unknown

UnknownNCT05602090

Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor Ovarian Reserve Patients

Status
Unknown
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Beni-Suef University · Academic / Other
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Accepted

Summary

Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients

Detailed description

To study the effect of growth hormone as adjuvant treatment on the outcomes of ICSI trials in poor ovarian reserve patients.

Conditions

Interventions

TypeNameDescription
DRUG4 IU of recombinant GH (Somatotropin )4 IU of recombinant GH

Timeline

Start date
2022-02-01
Primary completion
2023-09-04
Completion
2023-10-30
First posted
2022-11-01
Last updated
2023-04-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05602090. Inclusion in this directory is not an endorsement.

Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials (NCT05602090) · Clinical Trials Directory